Abstract
Gene therapy for AIDS based on RNA interference (RNAi) is currently looked upon as a promising alternative to conventional antiretroviral chemotherapy. The high variability of HIV-1 is the main challenge in developing new approaches to AIDS therapy. To date, about 18 million HIV-1 infected individuals receive antiretroviral therapy worldwide. As of 2017, about 44% of individuals with AIDS received antiretroviral therapy in Russia. Since the RNAs used for efficient RNAi and the corresponding targets in the viral transcript should be perfectly complementary to each other, it is necessary to continuously monitor the nucleotide sequences of clinical HIV-1 isolates obtained from blood and cells of naïve patients and patients receiving antiretroviral therapy. Comprehensive analysis of the mutation frequencies in the viral genome is only possible with deep sequencing approaches. The present paper reports on an analysis of the mutation frequencies in six 100 bp genome regions in clinical HIV-1 isolates obtained from blood plasma of four Russian AIDS patients who have been receiving antiretroviral therapy for several years. These regions contain efficient RNAi targets. The average frequencies of all possible transversions and transitions within the RNAi targets and in their proximity have been estimated. It has been demonstrated that reverse transcriptase inhibition decreases the frequency of a number of reverse mutations. It has been found that mutations in RNAi targets are rarer (5–75 times lower than the mutation frequency for different nucleotide substitutions) than in the adjacent sequences. Our findings speak in favor of these conservative targets for developing new approaches to gene therapy of AIDS.
Similar content being viewed by others
Abbreviations
- HIV-1:
-
human immunodeficiency virus type 1
- A1–A6:
-
virus genome regions about 100 bp in length containing efficient RNAi targets
- RT:
-
reverse transcriptase
References
Kretova O.V., Fedoseeva D.M., Gorbacheva M.A., Gashnikova N.M., Gashnikova M.P., Melnikova N.V., Chechetkin V.R., Kravatsky Y.V., Tchurikov N.A. 2017. Ultra-deep sequencing data of HIV-1–infected patients from Russia reveals six highly conserved targets of RNAi that are also present in many HIV-1 strains worldwide. Mol. Ther. Nucl. Acids. 8, 330–344. doi 10.1016/j.omtn.2017.07.010
Kretova O.V., Chechetkin V.R., Fedoseeva D.M., Kravatsky Y.V., Sosin D.V., Alembekov I.R., Gorbacheva M.A., Gashnikova N.M., Tchurikov N.A. 2016. Analysis of variability in HIV-1 subtype A strains in Russia suggests a combination of deep sequencing and multi-target RNA interference for silencing of the virus. AIDS Res. Hum. Retroviruses. 33, 194–201.
Tchurikov N.A., Fedoseeva D.M., Gashnikova N.M., Sosin D.V., Gorbacheva M.A., Alembekov I.R., Chechetkin V.R., Kravatsky Y.V., Kretova O.V. 2016. Conserved sequences in the current strains of HIV-1 subtype A in Russia are effectively targeted by artificial RNAi in vitro. Gene. 583, 78–83.
Kravatsky Y.V., Chechetkin V.R., Fedoseeva D.M., Gorbacheva M.A., Kretova O.V., Tchurikov N.A. 2016. Mutation frequencies in HIV-1 subtype A genomes in the regions containing the efficient RNAi targets. Mol. Biol. (Moscow). 50, 417–421. doi 10.7868/S0026898416020117
Kretova O.V., Gorbacheva M.A., Fedoseeva D.M., Kravatsky Y.V., Chechetkin V.R., Tchurikov N.A. 2018. Mutation frequences in HIV-1 genome in the regions containing the efficient RNAi targets, as calculated from the deep sequencing data. Mol. Biol. (Moscow). 52, in press.
Kravatsky Y., Chechetkin V., Fedoseeva D., Gorbacheva M., Kravatskaya G., Kretova O., Tchurikov N.A. 2017. Bioinformatic pipeline for monitoring of the mutational stability of viral drug targets with deepsequencing technology. Viruses. 9 (12), pii: E357. doi 10.3390/v9120357
Beerenwinkel N., Zagordi O. 2011. Ultra-deep sequencing for the analysis of viral population. Curr. Opin. Virol. 1, 413–418.
Pathak V.K., Temin H.M. 1990. Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proc. Natl. Acad. Sci. U. S. A. 87, 6019–6023.
Kim T., Mudry R.A.Jr., Rexrode C.A., Pathak V.K. 1996. Retroviral mutation rates and A-to-G hypermutations during different stages of retroviral replication. J. Virol. 70, 7594–7602.
Delviks-Frankenberry K.A., Nikolaitchik O.A., Burdick R.C., Gorelick R.J., Keele B.F., Hu W.-S., Pathak V.K. 2016. Minimal contribution of APOBEC3- induced G-to-A hypermutation to HIV-1 recombination and genetic variation. PLoS Pathog. 12 (5), e1005646. doi 10.1371/journal.ppat.1005646
Kwarteng A., Ahuno S.T., Kwakye-Nuako G. 2017. The therapeutic landscape of HIV-1 via genome editing. AIDS Res. Ther. 14 (1), 32. doi 10.1186/s12981-017-0157-8
Herrera-Carrillo E., Berkhout B. 2015. The impact of HIV-1 genetic diversity on the efficacy of a combinatorial RNAi-based gene therapy. Gene Ther. 22, 485–495. doi 10.1038/gt.2015.11
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © O.V. Kretova, M.A. Gorbacheva, D.M. Fedoseeva, Y.V. Kravatsky, V.R. Chechetkin, N.A. Tchurikov, 2018, published in Molekulyarnaya Biologiya, 2018, Vol. 52, No. 4, pp. 591–594.
Rights and permissions
About this article
Cite this article
Kretova, O.V., Gorbacheva, M.A., Fedoseeva, D.M. et al. Mutation Frequencies in RNAi Targets in HIV-1 Genomes Obtained from Blood Plasma of Patients Receiving Anti-Retroviral Therapy. Mol Biol 52, 510–513 (2018). https://doi.org/10.1134/S0026893318040118
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S0026893318040118